| Jian Li,Yimin Chen. Expression of PD-1/PD-L1 in lung adenocarcinoma and its clinical significance. Oncol Transl Med, 2021, 7: 15-19. |
| Expression of PD-1/PD-L1 in lung adenocarcinoma and its clinical significance |
| Received:August 09, 2020 Revised:February 27, 2021 |
| View Full Text View/Add Comment Download reader |
| KeyWord:lung adenocarcinoma; PD-1; PD-L1; gene mutation |
| Author Name | Affiliation | E-mail | | Jian Li | Emeishan people''s Hospital | zhongzhonglw199@aliyun.com | | Yimin Chen | Department of Respiration, Emeishan People's Hospital, Emeishan 614200, China | |
|
| Hits: 7251 |
| Download times: 9696 |
| Abstract: |
| Objective This study aimed to investigate PD-1/PD-L1 expression in lung adenocarcinoma and its
relationship with EGFR/KRAS mutation.
Methods The expression levels of PD-1 and PD-L1 in lung adenocarcinoma were detected.
Clinicopathological parameters were collected and followed up. The effects of PD-1 and PD-L1 expression
on clinicopathological parameters and prognosis of patients with lung adenocarcinoma were statistically
analyzed.
Results PD-L1 and PD-1 were mainly located in the membrane and cytoplasm of tumor cells. The
positive expression rates of PD-1 and PD-L1 were 53% and 40%, respectively. Positive PD-1 expression
had a significant effect on the incidence of KRAS mutation (P < 0.05), while PD-L1 expression significantly
affected the incidence of EGFR mutation (P < 0.05). Overexpression of PD-1 and PD-L1 had a significant
negative effect on disease-free survival (DFS) in patients with lung adenocarcinoma (P<0.05) but had no
significant effect on overall survival (P > 0.05). EGFR gene mutation, high PD-1 expression, high PD-L1
expression, N stage, and AJCC stage were independent risk factors of DFS (P < 0.05).
Conclusion High PD-1/PD-L1 expression is closely related to the occurrence of lung adenocarcinoma
and can be used as an independent factor to assess the prognosis of patients with lung adenocarcinoma.
There were negative correlations between PD-L1 expression and EGFR mutation and between PD-1
expression and KRAS mutation. |
| Close |
|
|
|